Press Release

IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize

Surprise Findings from First IntelliView 360™ Research Reveal Underserved Cancer Patient Population

WALTHAM, Mass. (Sep 15, 2009) IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the findings of the company’s first IntelliView 360™ research study. The biggest outcome: Oncologists believe they treat lung cancer patients in the maintenance setting three times more often than they actually do.

This study examines the use of maintenance therapy – an option for metastatic cancer patients to incrementally extend survival or improve their quality of life – in treating non-small cell lung cancer (NSCLC). Findings indicate that oncologists predominantly choose aggressive therapy followed by no treatment at all until the disease progresses, despite promising clinical data from maintenance use with drugs such as Alimta and Tarceva.

"The disconnect between attitudes and behavior shows that there is a large, untapped intent to treat with maintenance therapy," said Jeff Forringer, IntrinsiQ's president. "This represents a significant opportunity for the company that can figure out how to turn the intent into action. On the other hand, if you are developing a clinical trial for NSCLC, it is critical that you understand how this potential shift in treatment patterns could impact your trial design."

IntelliView 360, IntrinsiQ's custom research service behind this report, links oncologist practice information with primary research, to bridge the gap between actual patient treatment and oncologists' recall in surveys. It is the only reliable conduit to investigate cancer caregivers' behavior and answer questions of key importance, such as:

  • How big is the maintenance opportunity for our drug?
  • Are there patients we’re currently missing? What standard-of-care do they currently receive most often?
  • If we pursue clinical investigations in other settings, what will be the long-term impact on forecasts? On overall product positioning?
  • What clinical proof will convince physicians to treat a certain way?

To address key emerging issues in medical oncology, IntelliView 360 ties physicians’ attitudes, opinions, and views to IntrinsiQ data through a validated panel of medical and hematology oncologists – the same oncologists that use IntrinsiQ's flagship clinical software, IntelliDose®, to manage chemotherapy treatment. Panel members treat nearly 20,000 unique patients per month and practice in settings ranging from academic medical centers to hospitals to multispecialty private practices.

IntelliView 360 studies combine custom-designed, Web-based surveying from WWMR, a leading oncology primary research organization, with IntrinsiQ's longitudinal oncology practice data. WWMR became a division of IntrinsiQ in June 2009.

A complimentary market brief of IntrinsiQ's research findings is available by contacting Maria Rugani at (650) 513-0300 ext. 121, or Maria.Rugani@IntrinsiQ.com.

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ's clinical software application, IntelliDose®, captures the treatment decisions and details from more than 600 oncologists, for nearly 20,000 unique patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.

IntrinsiQ Company Contact

781-647-1144
info@intrinsiq.com

IntrinsiQ Media Contact

George Robertson
(617) 969-9192
grobertson@corporateink.com